Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder
Advisory: Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns
Be Prepared to Have the Difficult Conversation
Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings
Published: December 2021This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Advisory: Prescription Stimulant Misuse Among Youth and Young Adults
Published: November 2021This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.
Preventing Marijuana Use Among Youth
Treating Concurrent Substance Use Among Adults
TIP 63: Medications for Opioid Use Disorder - Executive Summary
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
TIP 63: Medications for Opioid Use Disorder - Full Document
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.